Travere Therapeutics, Inc.
TVTX
$28.35
$0.551.98%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 490.73M | 435.83M | 333.87M | 273.53M | 233.18M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 490.73M | 435.83M | 333.87M | 273.53M | 233.18M |
| Cost of Revenue | 216.35M | 220.55M | 220.38M | 225.88M | 225.24M |
| Gross Profit | 274.38M | 215.28M | 113.49M | 47.65M | 7.94M |
| SG&A Expenses | 337.20M | 305.01M | 284.17M | 272.73M | 264.12M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 553.55M | 525.55M | 504.55M | 498.62M | 489.36M |
| Operating Income | -62.82M | -89.73M | -170.68M | -225.09M | -256.18M |
| Income Before Tax | -49.27M | -88.55M | -169.10M | -225.93M | -320.51M |
| Income Tax Expenses | 988.00K | -5.00K | -97.00K | -32.00K | 120.00K |
| Earnings from Continuing Operations | -50.26 | -88.54 | -169.00 | -225.90 | -320.63 |
| Earnings from Discontinued Operations | 24.72M | 4.00K | -55.00K | -812.00K | -915.00K |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.55M | -88.54M | -169.06M | -226.71M | -321.55M |
| EBIT | -62.82M | -89.73M | -170.68M | -225.09M | -256.18M |
| EBITDA | -2.08M | -35.03M | -120.54M | -178.61M | -212.63M |
| EPS Basic | -0.29 | -1.05 | -2.04 | -2.81 | -4.10 |
| Normalized Basic EPS | -0.35 | -0.64 | -1.26 | -1.73 | -2.01 |
| EPS Diluted | -0.30 | -1.06 | -2.04 | -2.81 | -4.10 |
| Normalized Diluted EPS | -0.37 | -0.67 | -1.26 | -1.73 | -2.01 |
| Average Basic Shares Outstanding | 356.83M | 349.64M | 338.19M | 326.74M | 315.52M |
| Average Diluted Shares Outstanding | 370.21M | 363.03M | 338.19M | 326.74M | 315.52M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |